VieCure is collaborating with Labcorp to provide clinicians with greater access to precision oncology decision support. The collaboration aims to support patient-specific treatment plans by integrating Labcorp’s precision medicine testing solutions with VieCure’s clinical decision support tool, helping community cancer care providers advance health equity and increase precision diagnostic test utilization for cancer patients, including those living in rural and remote areas who may lack access to larger oncology centers.

Together, the two companies aim to improve clinical outcomes for patients, and to create a streamlined experience for biomarker-informed, personalized cancer care through an integrated clinic-genomic workflow of Labcorp’s precision medicine testing solutions.

“Nearly 75% of cancer patients in the United States are treated in the community and private practice settings,” says Fred Ashbury, PhD, chief scientific officer at VieCure. “We have an opportunity to help further democratize precision oncology and make it easier for community oncologists to offer the right care for the right patient every time.”

Next-generation sequencing (NGS) has become foundational for precision oncology, with rapidly expanding diagnostic, prognostic, and therapeutic implications, but a there are a number of challenges for data standards and interoperability that make it difficult for clinicians to effectively manage and stay up-to-date on potential treatments. Labcorp’s precision oncology test menu includes centralized solutions—including NGS-based tests spanning solid tumors, hematologic malignancies, and hereditary cancers‑and kitted solutions (through the Feb. 2022 acquisition of Personal Genome Diagnostics Inc.), allowing institutions to internalize NGS and provide testing in house and integrate comprehensive molecular data into patient records, the company says.

“Labcorp’s leadership and scale in precision medicine diagnostic testing and drug development will accelerate access to personalized treatments for cancer patients treated in community oncology practices,” says Prasanth Reddy, MD, MPH, FACP, senior vice president and global head of oncology at Labcorp. “Labcorp’s comprehensive portfolio of cancer diagnostic and next-generation sequencing products will be fully integrated into the VieCure platform, improving the clinical workflow experience for community oncologists to aid in precision medicine selection for oncology patients and drive better outcomes.”

Featured image: Labcorp’s comprehensive portfolio of cancer diagnostic and next-generation sequencing products will be fully integrated into the VieCure platform, improving the clinical workflow experience for community oncologists to aid in precision medicine selection for oncology patients and drive better outcomes. Photo: VieCure